Aminoglycoside prescribing and surveillance in cystic fibrosis

Am J Respir Crit Care Med. 2003 Mar 15;167(6):819-23. doi: 10.1164/rccm.200109-012CC.

Authors

Kelvin H-V Tan¹, Michael Mulheran, Alan J Knox, Alan R Smyth

Affiliation

¹ Division of Respiratory Medicine, Clinical Sciences Building, City Hospital, Hucknall Road, Nottingham NG5 1PB, UK. Kelvin.Tan@nottingham.ac.uk

PMID: 12623858
DOI: 10.1164/rccm.200109-012CC

No abstract available

Publication types

Research Support, Non-U.S. Gov't
Review

MeSH terms

Aminoglycosides
Anti-Bacterial Agents / adverse effects*
Anti-Bacterial Agents / pharmacokinetics
Anti-Bacterial Agents / therapeutic use*
Cystic Fibrosis / complications*
Cystic Fibrosis / metabolism
Drug Administration Schedule
Drug Monitoring / methods
Drug Monitoring / standards*
Drug Monitoring / statistics & numerical data
Drug Prescriptions / standards*
Drug Prescriptions / statistics & numerical data
Drug Utilization / standards
Drug Utilization / statistics & numerical data*
Hearing Disorders / chemically induced
Hearing Disorders / diagnosis
Hearing Disorders / epidemiology
Humans
Kidney Diseases / chemically induced
Kidney Diseases / diagnosis
Kidney Diseases / epidemiology
Kidney Function Tests
Patient Selection
Practice Guidelines as Topic
Practice Patterns, Physicians' / standards
Practice Patterns, Physicians' / statistics & numerical data
Prevalence
Prognosis
Risk Factors
Treatment Outcome

Substances

Aminoglycosides
Anti-Bacterial Agents